Use of bisphosphonates in multiple myeloma patients in Denmark, 2005-2015

Tina Bech Olesen, Ina Trolle Andersen, Anne Gulbech Ording, Vera Ehrenstein, Anouchka Seesaghur, Carsten Helleberg, Trine Silkjær, Rohini K Hernandez, Daniela Niepel, Niels Abildgaard


PURPOSE: To describe use of bisphosphonates in newly diagnosed multiple myeloma patients in Denmark.

METHODS: Using data from the Danish National Multiple Myeloma Registry, we conducted a population-based cohort study. Among patients newly diagnosed with multiple myeloma from 2005 to 2015, we examined use of bisphosphonates at first- and at progression/second-line anti-myeloma treatment overall, by patient characteristics, and myeloma complications.

RESULTS: Of 2947 patients starting first-line anti-myeloma treatment, 2207 patients (74.9%) received bisphosphonates. During a median follow-up of 27.6 (quartiles, 10.6-52.5) months, disease progression post-first-line treatment was recorded in 1546 patients, of whom 1065 (68.9%) were treated with bisphosphonates. Altogether, 80.9% of patients with and 37.6% of patients without myeloma bone disease were treated with bisphosphonates at first line and 73.0% and 42.7%, respectively, at progression/second line. Moreover, the proportion of patients treated with bisphosphonates decreased with increasing severity of renal impairment at first and at progression/second-line treatment.

CONCLUSION: The proportion of patients treated with bisphosphonates as part of first- and second-line anti-myeloma treatment increased with presence of myeloma bone disease and decreased by presence and severity of renal impairment. Overall, 25% of newly diagnosed multiple myeloma patients had no record of bisphosphonate treatment, potentially indicating an unmet need.

Original languageEnglish
JournalSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Issue number8
Pages (from-to)4501-4511
Number of pages11
Publication statusPublished - Aug 2021


  • Aged
  • Bone Density Conservation Agents/therapeutic use
  • Bone Neoplasms/drug therapy
  • Cohort Studies
  • Denmark
  • Diphosphonates/therapeutic use
  • Disease Progression
  • Female
  • Humans
  • Kidney Diseases/chemically induced
  • Male
  • Middle Aged
  • Multiple Myeloma/drug therapy
  • Registries
  • Severity of Illness Index
  • Multiple myeloma
  • Bisphosphonates
  • Epidemiology


Dive into the research topics of 'Use of bisphosphonates in multiple myeloma patients in Denmark, 2005-2015'. Together they form a unique fingerprint.

Cite this